NCT04307329View on ClinicalTrials.gov

Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

January 19, 2023

Study Completion Date

March 23, 2024

Conditions
Breast Cancer
Interventions
BIOLOGICAL

Monalizumab

Monalizumab 750 mg every two weeks

BIOLOGICAL

Trastuzumab

Trastuzumab 4 mg/kg every two weeks

Trial Locations (1)

Unknown

NKI-AVL, Amsterdam

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER